Table 5 Overall susceptibilities of organisms isolated from samples taken off after 48–72 h of admission

Amikacin (30 µg)

3/3 (100)

0/1 (0)

2/5 (40)

4/6 (66.67)

2/3 (67)

1/1 (100)

–

–

–

–

Augmentin (20/10 µg)

1/10 (10)

–

–

0/2 (0)

0/4 (0)

0/1 (0)

–

–

–

–

Ampicillin (10 µg)

0/11 (0)

–

–

0/1 (0)

0/4 (0)

–

–

–

–

1/1 (100)

Cefotaxime (30 µg)

1/4 (25)

–

–

0/2 (0)

–

–

–

–

–

–

Cefuroxime (30 µg)

1/11 (9.10)

–

–

–

0/4 (0)

–

–

–

–

–

Ceftazidime (30 µg)

1/9 (11.11)

0/1 (0)

2/5 (40)

2/10 (20.00)

0/4 (0)

0/1 (0)

–

–

–

–

Ceftriaxone (30 µg)

1/8 (12.50)

1/1 (100)

–

0/3 (0)

0/4 (0)

0/1 (0)

–

–

–

–

Cefepime (30 µg)

–

–

1/4 (25)

1/5 (20)

–

–

–

–

–

–

Ciprofloxacin (5 µg)

3/9 (33.33)

3/6 (50)

3/6 (50)

1/8 (12.05)

1/4 (25)

0/1 (0)

1/1 (100)

0/3 (0)

–

0/1 (0)

Chloramphenicol (30 µg)

2/9 (22.22)

3/4 (75)

–

0/2 (0)

0/4 (0)

–

0/1 (0)

0/1 (0)

1/1 (100)

0/1 (0)

Co-trimoxazole (1.25/23.5 µg)

0/10 (0)

0/4 (0)

–

0/8 (0)

0/5 (0)

0/1 (0)

0/1 (0)

0/2 (0)

–

–

Erythromycin (15 µg)

–

1/6 (16.67)

–

–

0/2 (0)

–

0/1 (0)

0/2 (0)

1/1 (100)

–

Oxacillin (1 µg)

–

1/4 (25)

–

–

2/2 (100)

–

0/1 (0)

1/2 (50)

–

–

Tetracycline (30 µg)

0/1 (0)

2/3 (66.67)

0/1 (0)

0/1 (0)

–

–

–

1/1 (100)

–

0/1 (0)

Penicillin G (10 µg)

1/4 (25)

–

–

0/2 (0)

–

–

0/2 (0)

0/1 (0)

–

Gentamicin (10 µg)

2/10 (20.00)

4/6 (66.67)

3/6 (50)

1/9 (11.11)

0/5 (0)

0/1 (0)

1/1 (100)

0/3 (0)

–

1/1 (100)

Imipenem (10 µg)

5/8 (62.5)

1/1 (100)

4/5 (80)

5/6 (83)

2/2 (100)

1/1 (100)

–

–

–

–

Piperacillin tazobactam (100/10 µg)

4/4 (100)

–

3/6 (50)

5/9 (55.56)

2/4 (50)

–

–

–

–

–

Meropenem (10 µg)

0/2 (0)

1/1 (100)

2/4 (50.00)

3/3 (100)

–

–

–

–

–

Vancomycin (30 µg)

–

5/6 (83.3)

–

–

–

–

1/1 (100)

2/2 (100)

1/1 (100)

1/1 (100)